Rosneblatt web panel_I0A4721 2

Archive for March 7th, 2014

Rosenblatt advises WH Ireland and WG Partners (a division of Charles Stanley & Co Limited) on a conditional placing, subscription and open offer by Verona Pharma plc to raise up to £14m

07/03/2014
Rosenblatt has advised WH Ireland Limited and WG Partners (a division of Charles Stanley & Co. Limited) on a conditional placing, subscription and open offer by Verona Pharma plc to raise up to ¬

Rosenblatt has advised WH Ireland Limited and WG Partners (a division of Charles Stanley & Co. Limited) on a conditional placing, subscription and open offer by Verona Pharma plc to raise up to £14m.  WH Ireland and WG Partners were joint brokers to Verona Pharma on the fundraising and WH Ireland is the company’s nominated adviser.

Verona Pharma is a drug development company focused on the development of high value, “first-in-class” drugs for severe, specialist-treated respiratory diseases.

The placing, subscription and open offer are conditional on, amongst other things, shareholder approval at a general meeting convened for 24 March 2014.   

Nick Foss-Pedersen from Rosenblatt’s corporate¬†team advised WH Ireland and WG Partners on the fund raising.

  • contact

    To contact us please complete this form

e-Bulletins